Barreling toward the loss of exclusivity on its blockbuster oncology therapy Keytruda, Merck & Co. has reportedly offered $3 ...

May was a terrible month for biotech, but June is (early days) looking better.

Merck has held talks to buy Swiss biotech MoonLake Immunotherapeutics for more than $3 billion, the Financial Times reported ...

MoonLake Immunotherapeutics' Sonelokimab's Phase 3 trials, PsA market growth, and Merck's $3B bid showcase potential. Read my ...

US drug giant Merck & Co Inc (NYSE:MRK) reportedly approached Swiss biotech MoonLake Immunotherapeutics (NASDAQ:MLTX) with a ...

In this article, we are going to take a look at where MoonLake Immunotherapeutics (NASDAQ:MLTX) stands against the other oversold biotech stocks to buy now. Biotechnology stocks are among the most ...

MoonLake Immunotherapeutics is a Cayman Islands domiciled, Zug, Switzerland headquartered clinical-stage biopharmaceutical concern focused on the development of its sonelokimab (SLK) therapy to ...

Zug, Switzerland, April 3, 2025 – MoonLake Immunotherapeutics (MoonLake; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases ...

MERCK has held talks to buy Swiss biotech MoonLake Immunotherapeutics for more than US$3 billion, the Financial Times ...